

## Type 2 diabetes in adults: management (medicines update) Guideline update – committee meeting 6

**Date:** Wednesday, 7<sup>th</sup> April 2021

**Location:** Virtual committee meeting by Zoom

**Minutes:** Final

<b>Committee members present:</b>		
Chizo Agwu (CA)	Chair	Present for notes 1 – 5
Chirag Bakhai	GP	Present for notes 1 – 5
Neel Basudev	GP	Present for notes 1 – 5
Augustin Brooks	Consultant Diabetologist	Present for notes 3 – 5
Anne Dornhorst	Consultant Diabetologist	Present for notes 1 – 5
Dorothy Frizelle	Mental health professional	Present for notes 1 – 5
Hugh Gallagher	Renal Physician	Present for notes 1 – 5
Natasha Jacques	Pharmacist	Present for notes 1 – 5
Sallianne Kavanagh	Pharmacist	Present for notes 1 – 5
Nicola Milne	Diabetes Nurse	Present for notes 1 – 5
Soon Song	Consultant Diabetologist	Present for notes 1 – 5
Annette Swinkels	Lay member	Present for notes 1 – 5
Gosia Wamil	Cardiologist	Present for notes 2 – 5
Corrinne Wykes	Lay member	Present for notes 1 – 5

<b>NICE team in attendance:</b>		
Lucy Beggs (LB)	Technical Adviser (Health Economics)	Present for notes 1 – 5
Becky Chadwick	Project Manager	Present for notes 1 – 5
Jacqueline Durkin	Administrator	Present for note 1 only
Gareth Franklin	Medicines Adviser	Present for notes 1 – 5
Rupert Franklin	Guideline Commissioning Manager	Present for notes 1 – 5
Anthony Gildea	Technical Analyst	Present for notes 1 – 5
Marie Harrisingh (MS)	Senior Technical Analyst	Present for notes 1 – 5
Kathryn Hopkins (KH)	Technical Adviser	Present for notes 1 – 5
Thomas Jones (TJ)	Technical Analyst (Health Economics)	Present for notes 1 – 5
Gregory Moran	Technical Analyst	Present for notes 1 – 5
Susan Spiers	Associate Director	Present for notes 1 – 5
Miaoqing Yang	NICE Observer	Present for notes 1 – 5

<b>Apologies:</b>	
Sarah Ali	Consultant Diabetologist
Sharon McCarthy	Diabetes Nurse

<b>1. Welcome, declarations of interest and minutes review</b>				
<p>The Chair welcomed the Committee members and attendees to the sixth committee meeting on Type 2 diabetes in adults (medicines update).</p> <p>The Chair informed the Committee that apologies had been received, noted above.</p> <p>The Chair asked everyone to verbally declare any interests that have arisen since the last meeting, these are noted below. The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.</p>				
<b>Name</b>	<b>Job title, organisation</b>	<b>Declarations of Interest, date declared</b>	<b>Type of interest</b>	<b>Decision taken</b>
Nicola Milne	Committee member, Nurse	Non-promotional GP Practice Meeting: Looking beyond HbA1c Honorarium Boehringer Ingelheim	Direct, financial	Declare and participate
Nicola Milne	Committee member, Nurse	Webinar: Panel discussion on NICE Guidelines in management of HF	Direct, financial	Declare and participate

		Honorarium from Omniaimed Communications Event Sponsored by AstraZeneca		
Hugh Gallagher	Committee member, Renal Physician	Member of the NHS London Kidney Network CKD Prevention steering group – part of the Early Identification workstream which involves case finding and implementation of urine protein testing.	Direct, non-financial professional and personal	Declare and participate

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.

## **2. Health economics queries for cardiovascular outcome trial (CVOT) review**

The Chair introduced Technical Adviser, Health Economics, Lucy Beggs (LB), and Technical Analysts, Health Economics, Thomas Jones (TJ) and Kusal Lokuge (KL), who presented the committee with some health economic queries in relation to the CVOT review.

The Chair thanked Thomas, Lucy and Kusal for their presentation and the Committee for their comments and feedback.

## **3. CVOT clinical review queries**

The Chair introduced Technical Analyst Gregory Moran (GM), who gave a clinical overview of the CVOT review and asked the committee for input on specific questions relating to the data used and the trials for inclusion in the CVOT review protocol.

The Chair thanked Greg for his presentation and the Committee for their feedback.

## **4. CKD review overview and questions**

The Chair introduced Technical Adviser Kathryn Hopkins (KH), who gave an overview of the review protocol for the effectiveness of SGLT2 inhibitors for people with chronic kidney disease and type 2 diabetes for the NICE draft guideline on chronic kidney disease.

Technical Adviser, Health Economics, Lucy Beggs (LB) then posed some health economics queries to the committee in relation to the CKD guideline update.

The Chair thanked Kathryn and Lucy for their presentations and the committee for their feedback.

## **5. AOB**

The Chair thanked the committee for their contribution, summarised the main actions from the day and asked if there was any other business.

As there was no further business, the Chair highlighted the date of the next meeting and brought

the meeting to a close.

**Date of next meeting:** Monday, 26<sup>th</sup> April (9:15 to 15:40)

**Location of next meeting:** Virtual committee meeting by Zoom